



UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

Office of the Director
Bureau of Competition

SEP 15 2009

M. Sean Royall, Esq.
2100 McKinney Avenue
Suite 1100
Dallas, TX 75201-6912

RE: Proposed Merger of Endocare, Inc. and Galil Medical Ltd., File No. 091-0026

Dear Mr. Royall:

The Federal Trade Commission's Bureau of Competition has been conducting a nonpublic investigation to determine whether the proposed merger between Endocare Inc. and Galil Medical Ltd. may violate Section 7 of the Clayton Act or Section 5 of the Federal Trade Commission Act or any other statute enforced by the Commission.

It now appears that no additional action is warranted by the Commission at this time. Accordingly, pursuant to authority delegated by the Commission, 49 Fed. Reg. 6171 (1984), the investigation has been closed. This action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that a violation has occurred. The Commission reserves the right to take such further action as the public interest may require.

Sincerely yours,

Richard A. Feinstein
Director
Bureau of Competition